Nektar Edges Into Immunotherapy With Better Interleukin-2 Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Building on foundation of IL-2 inhibition in immunotherapy, Nektar introduces an improved stimulatory cytokine available on outpatient basis, NKTR-214, for a number of tumor types.